fluorobenzenes has been researched along with Diabetes Mellitus, Adult-Onset in 68 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 22 (32.35) | 29.6817 |
| 2010's | 45 (66.18) | 24.3611 |
| 2020's | 1 (1.47) | 2.80 |
| Authors | Studies |
|---|---|
| Farooq Ur Rehman, RM; Khokhar, SA; Masood, S | 1 |
| D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Perrone, T | 1 |
| Camacho, X; Carter, AA; Gomes, T; Juurlink, DN; Mamdani, MM; Shah, BR | 1 |
| Arayne, MS; Sultana, N; Tabassum, A | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J; Vides, H | 1 |
| Arao, T; Hajime, M; Inokuchi, N; Kurozumi, A; Matsuoka, H; Mori, H; Narisawa, M; Okada, Y; Tanaka, K; Tanaka, Y; Torimoto, K; Yamamoto, S | 1 |
| Roberts, A | 1 |
| Singh, LP | 1 |
| An, F; Li, B; Liu, X; Luo, B; Wang, W; Xia, Y; Zhang, C; Zhang, M; Zhang, Y | 1 |
| Black, CA; Fleming, JW; Malinowski, SS; Miller, KH; Riche, DM; Wofford, MR | 1 |
| Barrett, PH; Chan, DC; Hamilton, SJ; Pang, J; Tenneti, VS; Watts, GF | 1 |
| Guo, C; He, L; Liu, HH; Liu, XD; Pan, GY; Ren, J; Sheng, JJ; Yang, Y; Yao, D; Zhou, WP | 1 |
| Higa, M; Ichijo, T; Katabami, T; Kobayashi, S; Matsui, T; Murakami, M; Ohta, A; Takagi, S; Tanaka, Y; Ujihara, M | 1 |
| Arneja, J; Shah, SN | 1 |
| Ding, Y; Liu, SS; Lou, JQ | 1 |
| Han, Y | 1 |
| Cecere, N; Jadoul, M; Labriola, L | 1 |
| Bajaj, M; Birnbaum, Y; Ling, S; Nanhwan, MK; Perez-Polo, JR; Ye, Y | 1 |
| Planchon, SM | 1 |
| Bae, KS; Choi, HY; Jeon, HS; Jung, JH; Kim, HJ; Kim, MJ; Kim, YH; Lee, SH; Lee, YK; Lim, HS | 1 |
| Everett, BM; Glynn, RJ; MacFadyen, J; Mora, S; Ridker, PM | 1 |
| Chan, KA; Chou, HW; Lai, CL; Lai, MS | 1 |
| Karpov, RS; Konko, TIu; Koshel'skaia, OA; Kravchenko, ES; Suslova, TE; Vinnitskaia, IV | 1 |
| Baillot-Rudoni, S; Duvillard, L; Florentin, E; Gambert, P; Monier, S; Petit, JM; Rageot, D; Vergès, B | 1 |
| Corretti, V; Ferrannini, E; Madec, S; Santini, E; Solini, A | 1 |
| Mandell, BF | 1 |
| Baillot-Rudoni, S; Brindisi, MC; Duvillard, L; Florentin, E; Gambert, P; Lagrost, L; Pais de Barros, JP; Petit, JM; Vergès, B | 1 |
| Hattori, Y; Kasai, K; Kase, H; Okayasu, T; Satoh, H; Suzuki, K; Tomizawa, A | 1 |
| Gratsianskiĭ, NA; Iavelov, IS; Masenko, VP; Polenova, NV; Vaulin, NA | 1 |
| Aso, Y; Inukai, T; Matsumoto, S; Suetsugu, M; Takebayashi, K | 1 |
| Bell, DS; O'Keefe, JH | 1 |
| Kuriyama, G; Mori, Y; Tajima, N; Tanaka, T | 1 |
| Kanazawa, I; Sugimoto, T; Yamaguchi, T; Yamauchi, M | 1 |
| Bellia, A; Cardillo, C; Donadel, G; Fabiano, R; Galli, A; Lauro, D; Lombardo, MF; Rizza, S; Sbraccia, P; Tesauro, M | 1 |
| Cusi, K; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC; Thakker, K | 1 |
| Averna, M; Brudi, P; Dong, Q; Farnier, M; Johnson-Levonas, AO; Missault, L; Shah, A; Vaverkova, H; Viigimaa, M | 1 |
| CAI, W; CHEN, LL; CHEN, ZY; FANG, J; LIN, YL; WU, LM | 1 |
| Bailey, C; Capps, N; Ramachandran, S; Saraf, S; Shetty, C | 1 |
| Koh, KK; Quon, MJ; Sakuma, I | 1 |
| Carlson, DM; Hirshberg, B; Kelly, MT; Rosenson, RS; Setze, CM; Stolzenbach, JC; Williams, LA | 1 |
| Ikeda, S; Kasai, K; Matsumura, M; Monden, T; Yanagi, K | 1 |
| Eeg-Olofsson, K; Eliasson, B; Gudbjörnsdóttir, S; Jonasson, JM; Miftaraj, M; Sundell, KA; Svensson, AM | 1 |
| Eren, MA; Koksal, M; Sabuncu, T; Turan, MN | 1 |
| Schalkwijk, CG; Simsek, S; Wolffenbuttel, BH | 1 |
| Crook, MA; Jewkes, C; Jones, A; Meek, C; Twomey, PJ; Viljoen, A; Wierzbicki, AS | 1 |
| Rehman, HU | 1 |
| Hitman, GA | 1 |
| Andreadi, K; Bellia, A; Cardillo, C; Donadel, G; Fabiano, R; Federici, M; Lauro, D; Lombardo, MF; Quon, MJ; Rizza, S; Sbraccia, P; Tesauro, M | 1 |
| Ooi, EM; Watts, GF | 1 |
| Glynn, RJ; Libby, P; MacFadyen, JG; Pradhan, A; Ridker, PM | 1 |
| Barrios, V; Escobar, C | 1 |
| Brito, JP; Montori, VM | 1 |
| Castiglioni, L; Cosentino, M; Dentali, F; Grandi, AM; Guasti, L; Legnaro, M; Maio, RC; Maresca, AM; Marino, F; Mongiardi, C; Rasini, E; Schembri, L | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J | 1 |
| Tuomilehto, J | 1 |
| Durrington, PN; Hamann, A; Kallend, D; Smith, K; Tuomilehto, J | 1 |
| Barter, PJ; Bonnet, J; Cheung, RC; Kallend, D; Morrell, JM; Raza, A; Schuster, H; Stender, S; Watkins, C | 1 |
| Franken, AA; Vincent, HH; Wolffenbuttel, BH | 1 |
| Kallend, D; Leiter, LA; Tuomilehto, J | 1 |
| Abbink, EJ; de Graaf, J; Holewijn, S; Stalenhoef, AF; Tack, CJ; ter Avest, E | 1 |
| Berne, C; Jørgensen, L; Sager, P; Siewert-Delle, A; Sorof, J | 1 |
| Miersch, S; Mutus, B; Raturi, A; Sliskovic, I | 1 |
| Betteridge, DJ; Gibson, JM | 1 |
| Bays, HE; Blasetto, JW; Fox, KM; Gandhi, SK; Ohsfeldt, RL | 1 |
| Betteridge, DJ; Gibson, JM; Sager, PT | 1 |
| Brunetti, ND; Casavecchia, GP; De Gennaro, L; Di Biase, M; Distaso, C; Maulucci, G; Pellegrino, PL | 1 |
| Coppey, LJ; Davidson, EP; Kleinschmidt, TL; Lund, DD; Oltman, CL; Yorek, MA | 1 |
5 review(s) available for fluorobenzenes and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Rediscovering bile acid sequestrants.
Topics: Allylamine; Anticholesteremic Agents; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fluorobenzenes; Humans; Hypoglycemic Agents; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2009 |
Differential metabolic effects of distinct statins.
Topics: Adiponectin; Animals; Atorvastatin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fluorobenzenes; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Mice; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Rosuvastatin and diabetes: when the evidences talk.
Topics: Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dyslipidemias; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2013 |
Reducing coronary heart disease associated with type 2 diabetes: lifestyle intervention and treatment of dyslipidaemia.
Topics: Body Weight; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fenofibrate; Fluorobenzenes; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Metformin; Motor Activity; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2003 |
A review of the efficacy of rosuvastatin in patients with type 2 diabetes.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2004 |
33 trial(s) available for fluorobenzenes and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Comparison of efficiency between Rosuvastatin and Atorvastatin in reducing low-density lipoprotein (LDL-C) in patients with diabetes mellitus.
Topics: Atorvastatin; Cholesterol, LDL; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2022 |
Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin.
Topics: Adipokines; Aged; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fatty Liver; Female; Fluorobenzenes; Glucose Clamp Technique; Glyburide; Humans; Hypoglycemic Agents; Inflammation Mediators; Insulin; Intra-Abdominal Fat; Italy; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Pyrimidines; Rosuvastatin Calcium; Subcutaneous Fat; Sulfonamides; Thiazolidinediones; Time Factors; Treatment Outcome; Ultrasonography | 2013 |
Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Obesity; Peptide Fragments; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes.
Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2013 |
Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kinetics; Male; Middle Aged; Models, Biological; Niacin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides; Up-Regulation; Western Australia | 2014 |
Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects.
Topics: Adult; Area Under Curve; Biphenyl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Fluorobenzenes; Healthy Volunteers; Humans; Hypoglycemic Agents; Irbesartan; Male; Middle Aged; Piperidones; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tetrazoles | 2015 |
Safety profile of subjects treated to very low low-density lipoprotein cholesterol levels (<30 mg/dl) with rosuvastatin 20 mg daily (from JUPITER).
Topics: Aged; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluorobenzenes; Hematuria; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Diseases; Male; Middle Aged; Odds Ratio; Proportional Hazards Models; Pyrimidines; Rosuvastatin Calcium; Sleep Initiation and Maintenance Disorders; Sulfonamides; Treatment Outcome | 2014 |
[Comparative Randomized Study of the Effects of Long-Term Therapy With Rosuvastatin and Combination of Atorvastatin and Ezetimibe on Carbohydrate Metabolism and Adipokines Levels in Patients With Coronary Artery Disease and Diabetes Mellitus].
Topics: Adipokines; Anticholesteremic Agents; Atorvastatin; Azetidines; Blood Glucose; Carbohydrate Metabolism; Coronary Artery Disease; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2015 |
Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes.
Topics: Apolipoproteins B; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lipoproteins, IDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Placebos; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2008 |
Effect of statins on soluble CD40 ligand in hypercholesterolemic Type 2 diabetic patients.
Topics: Albumins; Biomarkers; Blood Pressure; CD40 Ligand; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-6; Lipids; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes.
Topics: Aged; Apolipoprotein A-I; Blood Glucose; Carbon Isotopes; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lipoproteins, HDL; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2009 |
[Rosuvastatin and fenofibrate in patients with diabetes and low high density lipoprotein cholesterol: comparison of changes of lipid levels and some markers of inflammation].
Topics: Aged; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Fenofibrate; Fluorobenzenes; Follow-Up Studies; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Inflammation; Lipids; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
Effects of rosuvastatin and colestimide on metabolic parameters and urinary monocyte chemoattractant protein-1 in type 2 diabetic patients with hyperlipidemia.
Topics: C-Reactive Protein; Chemokine CCL2; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dinoprost; Enzyme-Linked Immunosorbent Assay; Epichlorohydrin; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Imidazoles; Male; Middle Aged; Oxidative Stress; Peptide Fragments; Prospective Studies; Pyrimidines; Resins, Synthetic; Retinol-Binding Proteins; Rosuvastatin Calcium; Sulfonamides | 2009 |
Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes.
Topics: Aged; Atorvastatin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
Rosuvastatin increased serum osteocalcin levels independent of its serum cholesterol-lowering effect in patients with type 2 diabetes and hypercholesterolemia.
Topics: Aged; Alkaline Phosphatase; Amino Acids; Azetidines; Bone and Bones; Cholesterol; Cholesterol, LDL; Collagen Type I; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Osteocalcin; Peptides; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2009 |
Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes.
Topics: Adiponectin; Adult; Blood Glucose; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Lipids; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tumor Necrosis Factor-alpha; Vasodilation | 2010 |
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy.
Topics: Anticholesteremic Agents; Apolipoproteins B; Azetidines; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Odds Ratio; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.
Topics: Anticholesteremic Agents; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2011 |
A crossover study of rosuvastatin and pitavastatin in patients with type 2 diabetes.
Topics: C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Monitoring; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Japan; Plasminogen Activator Inhibitor 1; Pyrimidines; Quinolines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides; Tumor Necrosis Factor-alpha | 2011 |
The effects of atorvastatin and rosuvastatin on oxidative stress in diabetic patients.
Topics: Adolescent; Adult; Aged; Antioxidants; Atorvastatin; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Oxidative Stress; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Young Adult | 2011 |
Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes---the CORALL study.
Topics: Atorvastatin; Blood Glucose; Coronary Disease; Diabetes Mellitus, Type 2; Fasting; Female; Fluorobenzenes; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Netherlands; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2012 |
Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy.
Topics: Adiponectin; Biomarkers; Blood Glucose; Brachial Artery; C-Reactive Protein; Chi-Square Distribution; Cross-Over Studies; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Fluorobenzenes; Glucose Clamp Technique; Glycated Hemoglobin; Homeostasis; Hospitals, University; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Leptin; Lipids; Male; Middle Aged; Pyrimidines; Rome; Rosuvastatin Calcium; Simvastatin; Single-Blind Method; Sulfonamides; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2012 |
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; United States; Venous Thromboembolism | 2012 |
Angiotensin II type 1 and type 2 receptor expression in circulating monocytes of diabetic and hypercholesterolemic patients over 3-month rosuvastatin treatment.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Monocytes; Pyrimidines; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Rosuvastatin Calcium; Sulfonamides | 2012 |
The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Blood Glucose; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Ezetimibe, Simvastatin Drug Combination; Fasting; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2013 |
Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
Topics: Adult; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2004 |
Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
Topics: Aged; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2004 |
Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2005 |
Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH).
Topics: Adult; Aged; Brachial Artery; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Insulin Resistance; Male; Middle Aged; Placebos; Plethysmography; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography; Vasodilation | 2005 |
Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients.
Topics: Aged; Albuminuria; Atorvastatin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Function Tests; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2006 |
Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2007 |
Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study).
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; England; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; North Carolina; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2007 |
Improvement in endothelium dysfunction in diabetics treated with statins: a randomized comparison of atorvastatin 20 mg versus rosuvastatin 10 mg.
Topics: Aged; Atorvastatin; C-Reactive Protein; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Pyrimidines; Pyrroles; Regional Blood Flow; Rosuvastatin Calcium; Sulfonamides; Vasodilation | 2007 |
30 other study(ies) available for fluorobenzenes and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Risk of incident diabetes among patients treated with statins: population based study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Odds Ratio; Ontario; Population Surveillance; Pravastatin; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2013 |
RP-LC simultaneous quantitation of co-administered drugs for (non-insulin dependent) diabetic mellitus induced dyslipidemia in active pharmaceutical ingredient, pharmaceutical formulations and human serum with UV-detector.
Topics: Adult; Anticholesteremic Agents; Calibration; Chromatography, Reverse-Phase; Diabetes Mellitus, Type 2; Dyslipidemias; Fluorobenzenes; Healthy Volunteers; Humans; Hypoglycemic Agents; Limit of Detection; Male; Metformin; Pyrimidines; Quality Control; Rosuvastatin Calcium; Sulfonamides; Sulfonylurea Compounds; Ultraviolet Rays | 2013 |
Prevention: Rosuvastatin can prevent contrast-induced AKI.
Topics: Acute Coronary Syndrome; Acute Kidney Injury; Angiography; Contrast Media; Coronary Angiography; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Humans; Male; Platelet Aggregation Inhibitors; Pyrimidines; Renal Insufficiency, Chronic; Sulfonamides | 2013 |
The NLRP3 inflammasome and diabetic cardiomyopathy : editorial to: "Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model" by Beibei Luo et al.
Topics: Animals; Carrier Proteins; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Fluorobenzenes; NLR Family, Pyrin Domain-Containing 3 Protein; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Rosuvastatin Calcium; Sulfonamides | 2014 |
Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model.
Topics: Animals; Blotting, Western; Carrier Proteins; Caspase 1; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Fluorobenzenes; Gene Silencing; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammasomes; Interleukin-1beta; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; NLR Family, Pyrin Domain-Containing 3 Protein; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Rosuvastatin Calcium; Sulfonamides | 2014 |
Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Diabetes Mellitus, Type 2; Drug Resistance; Drug Therapy, Combination; Dyslipidemias; Fatty Liver; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypoglycemic Agents; Male; Metabolic Syndrome; Middle Aged; Non-alcoholic Fatty Liver Disease; Obesity; Pioglitazone; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Thiazolidinediones | 2014 |
Opposite regulation of hepatic breast cancer resistance protein in type 1 and 2 diabetes mellitus.
Topics: Adult; Aged; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bile; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Glucose; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Liver; Liver Neoplasms; Male; Middle Aged; Neoplasm Proteins; Oleic Acid; Pyrimidines; Rats; Rats, Wistar; RNA, Messenger; Rosuvastatin Calcium; Sulfonamides | 2014 |
Efficacy of low-dose rosuvastatin in patients with type 2 diabetes and hypo high-density lipoprotein cholesterolaemia.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Creatine Kinase; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fluorobenzenes; Glucose; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, HDL; Male; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides; Young Adult | 2014 |
Efficacy of rosuvastatin in achieving target HDL, LDL, triglycerides and total cholesterol levels in type 2 diabetes mellitus (T2DM) with newly diagnosed dyslipidaemia: an open label, nonrandomised, non-interventional and observational study in India.
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2013 |
NLRP3, a potential therapeutic target for type 2 diabetes?
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Fluorobenzenes; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Sulfonamides | 2014 |
Reply: Intravenous hydration (with or without rosuvastatin) should remain the cornerstone of the prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease.
Topics: Acute Kidney Injury; Angiography; Contrast Media; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Humans; Male; Pyrimidines; Renal Insufficiency, Chronic; Sulfonamides | 2014 |
Intravenous hydration (with or without rosuvastatin) should remain the cornerstone of the prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease.
Topics: Acute Kidney Injury; Angiography; Contrast Media; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Humans; Male; Pyrimidines; Renal Insufficiency, Chronic; Sulfonamides | 2014 |
PTEN upregulation may explain the development of insulin resistance and type 2 diabetes with high dose statins.
Topics: Animals; Blood Glucose; Cilostazol; Diabetes Mellitus, Type 2; Diet, Western; Fluorobenzenes; Gene Knockdown Techniques; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Mice; Muscle, Skeletal; Phosphodiesterase 3 Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tetrazoles; Up-Regulation | 2014 |
Abrogating the induction of type 2 diabetes mellitus secondary to statin therapy.
Topics: Animals; Diabetes Mellitus, Type 2; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; PTEN Phosphohydrolase; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Up-Regulation | 2014 |
Effects of atorvastatin and rosuvastatin on renal function in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Atorvastatin; China; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Taiwan | 2015 |
Surprises and reaffirmations in 2008 clinical trials.
Topics: Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2009 |
Effects of statins on vascular endothelial function in hypercholesterolemic patients with type 2 diabetes mellitus: fluvastatin vs. rosuvastatin.
Topics: Antioxidants; Brachial Artery; C-Reactive Protein; Cholesterol; Diabetes Mellitus, Type 2; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ultrasonography; Vasodilation | 2010 |
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
New analysis supports expanded use of statins in women.
Topics: Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Health Knowledge, Attitudes, Practice; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Liver; Middle Aged; Muscular Diseases; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; United States; Women's Health | 2010 |
[Rosuvastatin enhances the protective effects of ischemic postconditioning on myocardial ischaemia-reperfusion injury in type 2 diabetic rat].
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Postconditioning; Male; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide Synthase Type III; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Rats; Rats, Wistar; Rosuvastatin Calcium; Signal Transduction; Sulfonamides | 2010 |
Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Clinical use and effectiveness of lipid lowering therapies in diabetes mellitus--an observational study from the Swedish National Diabetes Register.
Topics: Adolescent; Adult; Aged; Atorvastatin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Models, Statistical; Pyrimidines; Pyrroles; Registries; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Sweden; Treatment Outcome | 2011 |
Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study.
Topics: Aged; Alanine Transaminase; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Comorbidity; Creatine Kinase; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Smoking; Sulfonamides; Treatment Outcome; Triglycerides; United Kingdom | 2012 |
The work-up for mixed hyperlipidemia: a case study.
Topics: Adult; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Electrophoresis; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Lipoproteins; Male; Metformin; Physical Examination; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2012 |
Statins and glycaemic control--a cause for concern?
Topics: Atorvastatin; Blood Glucose; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2012 |
Balancing the cardiometabolic benefits and risks of statins.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2012 |
Statins induce hyperglycaemia of uncertain importance.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Sulfonamides | 2013 |
Antioxidant and antiplatelet effects of rosuvastatin in a hamster model of prediabetes.
Topics: Animals; Antioxidants; Blood Platelets; Cricetinae; Diabetes Mellitus, Type 2; Fluorobenzenes; Fructose; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mesocricetus; Nitric Oxide; Platelet Aggregation; Prediabetic State; Protein Disulfide-Isomerases; Pyrimidines; Reactive Oxygen Species; Rosuvastatin Calcium; Sulfonamides | 2007 |
Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective
Topics: Adult; Aged; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Medical Records Systems, Computerized; Middle Aged; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2007 |
Treatment of cardiovascular dysfunction associated with the metabolic syndrome and type 2 diabetes.
Topics: Age Factors; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Cholesterol; Coronary Vessels; Diabetes Mellitus, Type 2; Enalapril; Endothelium, Vascular; Fatty Acids; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mesenteric Arteries; Metabolic Syndrome; Oxidative Stress; Pyrimidines; Rats; Rats, Zucker; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2008 |